留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

血红蛋白类氧载体在肾移植中的应用前景

王欢 周文涛 刘嘉馨 王红

王欢, 周文涛, 刘嘉馨, 等. 血红蛋白类氧载体在肾移植中的应用前景[J]. 器官移植, 2021, 12(6): 754-760. doi: 10.3969/j.issn.1674-7445.2021.06.017
引用本文: 王欢, 周文涛, 刘嘉馨, 等. 血红蛋白类氧载体在肾移植中的应用前景[J]. 器官移植, 2021, 12(6): 754-760. doi: 10.3969/j.issn.1674-7445.2021.06.017
Wang Huan, Zhou Wentao, Liu Jiaxin, et al. Application prospect of hemoglobin-based oxygen carrier in kidney transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(6): 754-760. doi: 10.3969/j.issn.1674-7445.2021.06.017
Citation: Wang Huan, Zhou Wentao, Liu Jiaxin, et al. Application prospect of hemoglobin-based oxygen carrier in kidney transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(6): 754-760. doi: 10.3969/j.issn.1674-7445.2021.06.017

血红蛋白类氧载体在肾移植中的应用前景

doi: 10.3969/j.issn.1674-7445.2021.06.017
基金项目: 

四川省科技计划项目 2021YJ0122

详细信息
    作者简介:

    王欢,女,1996年生,硕士研究生,研究方向为血液代用品,Email: wh1945508697@163.com

    通讯作者:

    王红,女,1968年生,主任技师,研究方向为血液代用品、血液保存、输血材料及相关医疗器械,Email: smile9918@126.com

  • 中图分类号: R617, R331.1+41

Application prospect of hemoglobin-based oxygen carrier in kidney transplantation

More Information
  • 摘要: 高质量的供器官对于移植成功至关重要,但随着肾衰竭患者的增多,标准供者已无法满足现阶段的移植需求,边缘供肾开始广泛应用于临床,这也对现有供肾保存方法提出了挑战。缺血-再灌注损伤(IRI)是影响肾移植术后早期移植物功能的重要因素之一,并且对移植物的长期存活产生有害影响。现有研究发现,血红蛋白类氧载体(HBOC)能够减轻肾移植过程中的IRI,有效改善供肾保存质量,延长供肾保存时间。本文综述了HBOC在肾移植中的研究进展,以期为改善供肾保存方法、提高供肾质量、改善受者预后提供参考。

     

  • 表  1  HBOC在器官保存中的应用的文献报道

    Table  1.   Literature reports on the application of HBOC in organ preservation

    研究者 年份 HBOC种类 来源 器官种类 保存方式 研究进展
    Matton, et al[38] 2018 HBOC-201 牛血 人肝脏 NMP 临床前研究
    Aburawi, et al[12] 2019 HBOC-201 牛血 人肾脏 NMP 临床前研究
    Bhattacharjee, et al[39] 2020 HBOC-201 牛血 猪肾脏 SNMP 临床前研究
    Mahboub, et al[40] 2020 HBOC-201 牛血 大鼠肾脏 逐渐复温灌注 临床前研究
    Shonaka, et al[20] 2018 HbV 人血 猪肝脏 SNMP 临床前研究(起步阶段)
    Thuillier, et al[41] 2011 M101 海洋无脊椎动物 猪肾脏 冷保存 临床前研究
    Mallet, et al[42] 2014 M101 海洋无脊椎动物 猪肾脏 冷保存 临床前研究
    Yannick, et al 2016 M101 海洋无脊椎动物 人肾脏 机械灌注 临床研究(NCT02652520,已完成)
    Teh, et al[43] 2017 M101 海洋无脊椎动物 大鼠心脏 冷保存 临床前研究
    Glorion, et al[44] 2018 M101 海洋无脊椎动物 猪肺脏 冷保存 临床前研究
    Kasil, et al[45] 2019 M101 海洋无脊椎动物 猪肾脏 机械灌注 临床前研究
    Kaminski, et al[46] 2019 M101 海洋无脊椎动物 猪肾脏 冷保存、机械灌注 临床前研究
    Yannick, et al 2020 M101 海洋无脊椎动物 人肾脏 - 临床研究(NCT04181710,研究中)
    Fontes, et al[47] 2015 HemopureTM 牛血 猪肝脏 SNMP 临床前研究(起步阶段)
    注:①HbV为血红蛋白胶囊。
           ②研究中尚未发表。
           ③-为无数据。
    下载: 导出CSV
  • [1] KALANTAR-ZADEH K, LI PK. Strategies to prevent kidney disease and its progression[J]. Nat Rev Nephrol, 2020, 16(3): 129-130. DOI: 10.1038/s41581-020-0253-1.
    [2] THOMPSON ER, CONNELLY C, ALI S, et al. Cell therapy during machine perfusion[J]. Transpl Int, 2021, 34(1): 49-58. DOI: 10.1111/tri.13780.
    [3] MIRSHEKAR-SYAHKAL B, SUMMERS D, BRADBURY LL, et al. Local expansion of donation after circulatory death kidney transplant activity improves waitlisted outcomes and addresses inequities of access to transplantation[J]. Am J Transplant, 2017, 17(2): 390-400. DOI: 10.1111/ajt.13968.
    [4] THUILLIER R, HAUET T. Impact of hypothermia and oxygen deprivation on the cytoskeleton in organ preservation models[J]. Biomed Res Int, 2018: 8926724. DOI: 10.1155/2018/8926724.
    [5] WONG G, TEIXEIRA-PINTO A, CHAPMAN JR, et al. The impact of total ischemic time, donor age and the pathway of donor death on graft outcomes after deceased donor kidney transplantation[J]. Transplantation, 2017, 101(6): 1152-1158. DOI: 10.1097/TP.0000000000001351.
    [6] TEJCHMAN K, SIEROCKA A, KOTOWSKI M, et al. Acid-base balance disorders during kidney preservation in cold ischemia[J]. Transplant Proc, 2020, 52(7): 2036-2042. DOI: 10.1016/j.transproceed.2020.01.099.
    [7] JING L, YAO L, ZHAO M, et al. Organ preservation: from the past to the future[J]. Acta Pharmacol Sin, 2018, 39(5): 845-857. DOI: 10.1038/aps.2017.182.
    [8] STEICHEN C, GIRAUD S, BON D, et al. Barriers and advances in kidney preservation[J]. Biomed Res Int, 2018: 9206257. DOI: 10.1155/2018/9206257.
    [9] ROSENBERGER C, ECKARDT KU. Oxygenation of the transplanted kidney[J]. Semin Nephrol, 2019, 39(6): 554-566. DOI: 10.1016/j.semnephrol.2019.10.005.
    [10] LEMAIRE F, SIGRIST S, DELPY E, et al. Beneficial effects of the novel marine oxygen carrier M101 during cold preservation of rat and human pancreas[J]. J Cell Mol Med, 2019, 23(12): 8025-8034. DOI: 10.1111/jcmm.14666.
    [11] 中华医学会器官移植学分会. 供肾灌注、保存及修复技术操作规范(2019版)[J]. 器官移植, 2019, 10(5): 473-477. DOI: 10.3969/j.issn.1674-7445.2019.05.002.

    Branch of Organ Transplantation of Chinese Medical Association. Technical operation specification for perfusion, preservation and repair of donor kidney (2019 edition)[J]. Organ Transplant, 2019, 10(5): 473-477. DOI: 10.3969/j.issn.1674-7445.2019.05.002.
    [12] ABURAWI MM, FONTAN FM, KARIMIAN N, et al. Synthetic hemoglobin-based oxygen carriers are an acceptable alternative for packed red blood cells in normothermic kidney perfusion[J]. Am J Transplant, 2019, 19(10): 2814-2824. DOI: 10.1111/ajt.15375.
    [13] LAING RW, BHOGAL RH, WALLACE L, et al. The use of an acellular oxygen carrier in a human liver model of normothermic machine perfusion[J]. Transplantation, 2017, 101(11): 2746-2756. DOI: 10.1097/TP.0000000000001821.
    [14] VARNEY J, RIVERA A, DONG V, et al. Mini-review on the properties and possible applications of therapeutic oxygen carrier Hemarina-M101[J]. Transfus Apher Sci, 2021, 60(1): 103016. DOI: 10.1016/j.transci.2020.103016.
    [15] GIRAUD S, THUILLIER R, CAU J, et al. In vitro/ex vivo models for the study of ischemia reperfusion injury during kidney perfusion[J]. Int J Mol Sci, 2020, 21(21): 8156. DOI: 10.3390/ijms21218156.
    [16] HOSGOOD SA, NICHOLSON ML. Organ retrieval and preservation[J]. Surgery (Oxford), 2014, 32(7): 338-343.
    [17] HAN SJ, LEE HT. Mechanisms and therapeutic targets of ischemic acute kidney injury[J]. Kidney Res Clin Pract, 2019, 38(4): 427-440. DOI: 10.23876/j.krcp.19.062.
    [18] DARIUS T, GIANELLO P, VERGAUWEN M, et al. The effect on early renal function of various dynamic preservation strategies in a preclinical pig ischemia-reperfusion autotransplant model[J]. Am J Transplant, 2019, 19(3): 752-762. DOI: 10.1111/ajt.15100.
    [19] NICHOLSON ML, HOSGOOD SA. Renal transplantation after ex vivo normothermic perfusion: the first clinical study[J]. Am J Transplant, 2013, 13(5): 1246-1252. DOI: 10.1111/ajt.12179.
    [20] SHONAKA T, MATSUNO N, OBARA H, et al. Application of perfusate with human-derived oxygen carrier solution under subnormothermic machine perfusion for donation after cardiac death liver grafts in pigs[J]. Transplant Proc, 2018, 50(9): 2821-2825. DOI: 10.1016/j.transproceed.2018.02.184.
    [21] MINOR T, VON HORN C, PAUL A. Role of erythrocytes in short-term rewarming kidney perfusion after cold storage[J]. Artif Organs, 2019, 43(6): 584-592. DOI: 10.1111/aor.13403.
    [22] FLATMARK A, SLAATTELID O, WOXHOLT G. Gaseous persufflation during machine perfusion of human kidneys before transplantation[J]. Eur Surg Res, 1975, 7(2): 83-90. DOI: 10.1159/000127794.
    [23] KALENSKI J, MANCINA E, PASCHENDA P, et al. Comparison of aerobic preservation by venous systemic oxygen persufflation or oxygenated machine perfusion of warm-ischemia-damaged porcine kidneys[J]. Eur Surg Res, 2016, 57(1/2): 10-21. DOI: 10.1159/000444851.
    [24] THUILLIER R, DELPY E, MATILLON X, et al. Preventing acute kidney injury during transplantation: the application of novel oxygen carriers[J]. Expert Opin Investig Drugs, 2019, 28(7): 643-657. DOI: 10.1080/13543784.2019.1628217.
    [25] COPPOLINO G, LEONARDI G, ANDREUCCI M, et al. Oxidative stress and kidney function: a brief update[J]. Curr Pharm Des, 2018, 24(40): 4794-4799. DOI: 10.2174/1381612825666190112165206.
    [26] VASKO R. Peroxisomes and kidney injury[J]. Antioxid Redox Signal, 2016, 25(4): 217-231. DOI: 10.1089/ars.2016.6666.
    [27] SCHOLZ H, BOIVIN FJ, SCHMIDT-OTT KM, et al. Kidney physiology and susceptibility to acute kidney injury: implications for renoprotection[J]. Nat Rev Nephrol, 2021, 17(5): 335-349. DOI: 10.1038/s41581-021-00394-7.
    [28] DUANN P, LIN PH. Mitochondria damage and kidney disease[J]. Adv Exp Med Biol, 2017, 982: 529-551. DOI: 10.1007/978-3-319-55330-6_27.
    [29] DELPECH PO, THUILLIER R, LE PAPE S, et al. Effects of warm ischaemia combined with cold preservation on the hypoxia-inducible factor 1α pathway in an experimental renal autotransplantation model[J]. Br J Surg, 2014, 101(13): 1739-1750. DOI: 10.1002/bjs.9611.
    [30] HALDAR R, GUPTA D, CHITRANSHI S, et al. Artificial blood: a futuristic dimension of modern day transfusion sciences[J]. Cardiovasc Hematol Agents Med Chem, 2019, 17(1): 11-16. DOI: 10.2174/1871525717666190617120045.
    [31] ALAYASH AI. Blood substitutes: why haven't we been more successful?[J]. Trends Biotechnol, 2014, 32(4): 177-185. DOI: 10.1016/j.tibtech.2014.02.006.
    [32] SEN GUPTA A. Hemoglobin-based oxygen carriers: current state-of-the-art and novel molecules[J]. Shock, 2019, 52(1S Suppl 1): 70-83. DOI: 10.1097/SHK.0000000000001009.
    [33] VRSELJA Z, DANIELE SG, SILBEREIS J, et al. Restoration of brain circulation and cellular functions hours post-mortem[J]. Nature, 2019, 568(7752): 336-343. DOI: 10.1038/s41586-019-1099-1.
    [34] SPAHN DR. Artificial oxygen carriers: a new future?[J]. Crit Care, 2018, 22(1): 46. DOI: 10.1186/s13054-018-1949-5.
    [35] KUZMIAK-GLANCY S, COVIAN R, FEMNOU AN, et al. Cardiac performance is limited by oxygen delivery to the mitochondria in the crystalloid-perfused working heart[J]. Am J Physiol Heart Circ Physiol, 2018, 314(4): H704-H715. DOI: 10.1152/ajpheart.00321.2017.
    [36] HOSGOOD SA, NICHOLSON ML. The role of perfluorocarbon in organ preservation[J]. Transplantation, 2010, 89(10): 1169-1175. DOI: 10.1097/TP.0b013e3181da6064.
    [37] HOSGOOD SA, MOHAMED IH, NICHOLSON ML. The two layer method does not improve the preservation of porcine kidneys[J]. Med Sci Monit, 2011, 17(1): BR27-BR33. DOI: 10.12659/msm.881326.
    [38] MATTON APM, BURLAGE LC, VAN RIJN R, et al. Normothermic machine perfusion of donor livers without the need for human blood products[J]. Liver Transpl, 2018, 24(4): 528-538. DOI: 10.1002/lt.25005.
    [39] BHATTACHARJEE RN, PATEL SVB, SUN Q, et al. Renal protection against ischemia reperfusion injury: hemoglobin-based oxygen carrier-201 versus blood as an oxygen carrier in ex vivo subnormothermic machine perfusion[J]. Transplantation, 2020, 104(3): 482-489. DOI: 10.1097/TP.0000000000002967.
    [40] MAHBOUB P, ABURAWI M, KARIMIAN N, et al. The efficacy of HBOC-201 in ex situ gradual rewarming kidney perfusion in a rat model[J]. Artif Organs, 2020, 44(1): 81-90. DOI: 10.1111/aor.13534.
    [41] THUILLIER R, DUTHEIL D, TRIEU MT, et al. Supplementation with a new therapeutic oxygen carrier reduces chronic fibrosis and organ dysfunction in kidney static preservation[J]. Am J Transplant, 2011, 11(9): 1845-1860. DOI: 10.1111/j.1600-6143.2011.03614.x.
    [42] MALLET V, DUTHEIL D, POLARD V, et al. Dose-ranging study of the performance of the natural oxygen transporter HEMO2 Life in organ preservation[J]. Artif Organs, 2014, 38(8): 691-701. DOI: 10.1111/aor.12307.
    [43] TEH ES, ZAL F, POLARD V, et al. HEMO2life as a protective additive to Celsior solution for static storage of donor hearts prior to transplantation[J]. Artif Cells Nanomed Biotechnol, 2017, 45(4): 717-722. DOI: 10.1080/21691401.2016.1265974.
    [44] GLORION M, POLARD V, FAVEREAU F, et al. Prevention of ischemia-reperfusion lung injury during static cold preservation by supplementation of standard preservation solution with HEMO2life® in pig lung transplantation model[J]. Artif Cells Nanomed Biotechnol, 2018, 46(8): 1773-1780. DOI: 10.1080/21691401.2017.1392315.
    [45] KASIL A, GIRAUD S, COUTURIER P, et al. Individual and combined impact of oxygen and oxygen transporter supplementation during kidney machine preservation in a porcine preclinical kidney transplantation model[J]. Int J Mol Sci, 2019, 20(8): 1992. DOI: 10.3390/ijms20081992.
    [46] KAMINSKI J, HANNAERT P, KASIL A, et al. Efficacy of the natural oxygen transporter HEMO2 life® in cold preservation in a preclinical porcine model of donation after cardiac death[J]. Transpl Int, 2019, 32(9): 985-996. DOI: 10.1111/tri.13434.
    [47] FONTES P, LOPEZ R, VAN DER PLAATS A, et al. Liver preservation with machine perfusion and a newly developed cell-free oxygen carrier solution under subnormothermic conditions[J]. Am J Transplant, 2015, 15(2): 381-394. DOI: 10.1111/ajt.12991.
    [48] KHAN F, SINGH K, FRIEDMAN MT. Artificial blood: the history and current perspectives of blood substitutes[J]. Discoveries (Craiova), 2020, 8(1): e104. DOI: 10.15190/d.2020.1.
    [49] LE MEUR Y, BADET L, ESSIG M, et al. First-in-human use of a marine oxygen carrier (M101) for organ preservation: a safety and proof-of-principle study[J]. Am J Transplant, 2020, 20(6): 1729-1738. DOI: 10.1111/ajt.15798.
    [50] 何晓顺, 鞠卫强, 朱泽斌. "无缺血"器官移植时代的来临与展望[J/CD]. 中华普通外科学文献(电子版), 2018, 12(2): 73-75. DOI: 10.3877/cma.j.issn.1674-0793.2018.02.001.

    HE XS, JU WQ, ZHU ZB. The coming and prospect of the era of "no ischemic" organ transplantation[J/CD]. Chin Arch Gen Surg (Electr Edit), 2018, 12(2): 73-75. DOI: 10.3877/cma.j.issn.1674-0793.2018.02.001.
  • 加载中
图(1) / 表(1)
计量
  • 文章访问数:  65
  • HTML全文浏览量:  11
  • PDF下载量:  12
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-07-01
  • 刊出日期:  2021-11-15

目录

    /

    返回文章
    返回